HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Deal Would Aid Afexa’s Cold-FX Expansion Plans

This article was originally published in The Tan Sheet

Executive Summary

Valeant Pharmaceuticals International’s acquisition of Afexa Health Sciences likely will boost efforts to transition Afexa’s Cold-FX from a Canadian natural health product to a U.S. pharmaceutical.

You may also be interested in...

People In Brief

CHPA scientists Schneider, Roehrig exit

In Brief

CHPA defends phytosterol claim

Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path

Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts